source
- TScan Therapeutics cuts 75% of staff to focus on preclinical solid tumor programsTScan Therapeutics said it will cut about three quarters of its workforce after pausing its hematological and autoimmune programs. The company will shift resources to its preclinical solid tumor p…
- Trump’s new pharma deals lower Medicaid prices but shield Medicare from cutsWashington officials announced new voluntary pricing agreements with several midsize biotechnology companies. The deals require the firms to reduce the prices they charge under Medicaid, the progra…